These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36495632)

  • 1. 1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells.
    Zhao S; Ali AS; Kong X; Zhang Y; Liu X; Skidmore MA; Forsyth CM; Savage GP; Wu D; Xu Y; Francis CL
    Eur J Med Chem; 2023 Jan; 246():114982. PubMed ID: 36495632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells.
    Zhao S; Ali AS; Liu X; Yu Z; Kong X; Zhang Y; Paul Savage G; Xu Y; Lin B; Wu D; Francis CL
    Bioorg Med Chem; 2024 Mar; 101():117634. PubMed ID: 38359754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
    Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
    Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist.
    Cole RN; Chen W; Pascal LE; Nelson JB; Wipf P; Wang Z
    Mol Cancer Ther; 2022 Apr; 21(4):483-492. PubMed ID: 35058329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside compound K suppresses tumour growth in the 22Rv1 xenograft model and inhibits androgenic responses via the transcriptional mechanism in human prostate cancer cells.
    Jiang M; Sun Y; Song K
    FEBS J; 2023 Apr; 290(7):1840-1854. PubMed ID: 36349420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
    Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
    [No Abstract]   [Full Text] [Related]  

  • 11. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artepillin C overcomes apalutamide resistance through blocking androgen signaling in prostate cancer cells.
    Ota A; Kawai M; Kudo Y; Segawa J; Hoshi M; Kawano S; Yoshino Y; Ichihara K; Shiota M; Fujimoto N; Matsunaga T; Endo S; Ikari A
    Arch Biochem Biophys; 2023 Feb; 735():109519. PubMed ID: 36642262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
    Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA
    Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
    Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
    Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2.
    Ehsani M; Bartsch S; Rasa SMM; Dittmann J; Pungsrinont T; Neubert L; Huettner SS; Kotolloshi R; Schindler K; Ahmad A; Mosig AS; Adam L; Ori A; Neri F; Berndt A; Grimm MO; Baniahmad A
    Oncogene; 2022 Jun; 41(23):3263-3277. PubMed ID: 35513564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.